top of page

Crizotinib may be effective again after chemo

Updated: Feb 15, 2022

Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC.


This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance.


Read full article here.

2 views0 comments
bottom of page